1. Name and Address of Reporting Person *
   DeLong Mark Jeffrey
   ______________________________  ______________________________  ______________________________
   (Last)  (First)  (Middle)
   C/O APELLIS PHARMACEUTICALS, INC.
   100 FIFTH AVENUE, 3RD FLOOR
   WALTHAM  MA  02451

2. Issuer Name and Ticker or Trading Symbol
   Apellis Pharmaceuticals, Inc. [ APLS ]

3. Date of Earliest Transaction (Month/Day/Year)
   08/08/2022

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
   Director
   10% Owner
   Officer (give title below)
   Senior Vice President
   Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

---

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>08/08/2022</td>
<td></td>
<td>M(1)</td>
<td>5,000 A</td>
<td>$15.52</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/08/2022</td>
<td></td>
<td>S(1)</td>
<td>5,000 D</td>
<td>$64.5</td>
<td>D</td>
</tr>
</tbody>
</table>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$15.52</td>
<td>08/08/2022</td>
<td></td>
<td>M(1)</td>
<td>5,000 (A)</td>
<td>02/04/2028</td>
<td>Common Stock</td>
<td>5,000</td>
<td>$0</td>
<td>10,000 D</td>
<td></td>
</tr>
</tbody>
</table>

**Explanation of Responses:**

1. This is a scheduled exercise and sale from an established 1085-1 trading plan.
2. This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.

/s/ David Watson, attorney-in-fact for Mark DeLong 08/09/2022
** Signature of Reporting Person  Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.